Experienced in Sertoli-Leydig Cell Tumor

Dr. Karthik Koduru

Hematology Oncology | Hospital Medicine | Hematology
Dallas, TX 
Experienced in Sertoli-Leydig Cell Tumor
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Karthik Koduru is a Hematologist Oncology specialist and a Hospital Medicine provider in Dallas, Texas. Dr. Koduru is rated as an Experienced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Small Cell Lung Cancer (SCLC), Colonoscopy, and Endoscopy.

His clinical research consists of participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hospital Medicine
Hematology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

Dallas, TX 75265

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Fulvestrant
Study Phase: Phase 3
View 2 Less Clinical Trials
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Kathleen M. Crowley
Hematology Oncology | Hematology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Kathleen M. Crowley
Hematology Oncology | Hematology | Oncology

Acclaim Physician Group Inc

1350 S Main St, Suite 1600, 
Fort Worth, TX 
 (30.4 miles away)
817-702-9701
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kathleen Crowley is a Hematologist Oncology specialist and a Hematologist in Fort Worth, Texas. Dr. Crowley is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Sickle Cell Disease, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Cervical Cancer. Dr. Crowley is currently accepting new patients.

Advanced in Sertoli-Leydig Cell Tumor
Dr. Ma A. Athar
Hematology Oncology | Oncology | Hematology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Ma A. Athar
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

10425 N Central Expy, 
Dallas, TX 
 (7.6 miles away)
214-361-2025
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ma Athar is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Dr. Athar is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Paget Disease of the Breast, and Familial Pancreatic Cancer. Dr. Athar is currently accepting new patients.

Advanced in Sertoli-Leydig Cell Tumor
Dr. Nicole S. Bartosh
Oncology | Hematology Oncology | Hematology
Advanced in Sertoli-Leydig Cell Tumor
Dr. Nicole S. Bartosh
Oncology | Hematology Oncology | Hematology

Oncology-Hematology Consultants PA

920 Santa Fe Dr, 
Weatherford, TX 
 (56.9 miles away)
817-596-0637
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Nicole Bartosh is an Oncologist and a Hematologist Oncology provider in Weatherford, Texas. Dr. Bartosh is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Paget Disease of the Breast, Non-Hodgkin Lymphoma, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Bartosh is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Koduru's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 93 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile